放疗前中性粒细胞与淋巴细胞比值对局部晚期非小细胞肺癌患者的预后价值
该回顾性研究分析了420例接受胸部放疗的局部晚期非小细胞肺癌患者,通过ROC曲线确定放疗前NLR最佳界值为2.1,发现高NLR组5年无进展生存率和总生存率均显著低于低NLR组,多因素分析证实放疗前NLR是总生存的独立预后因素。
要点
- 放疗前NLR最佳界值为2.1,高NLR组5年PFS和OS均显著更差。
- 多因素分析显示放疗前NLR是局部晚期NSCLC患者OS的独立预后因素。
- NLR受患者状态和治疗影响较大,其预后价值仍需进一步研究。
核心结论
- 放疗前NLR升高是接受胸部放疗的局部晚期NSCLC患者独立的不良预后因素。
研究设计与样本
- 回顾性分析2007年1月至2010年12月收治的420例接受单纯放疗、序贯放化疗或同步放化疗的局部晚期NSCLC患者。
主要发现
- 全组中位随访时间5.2年,中位总生存时间22个月,345例死亡,75例生存。
- 高NLR组与低NLR组5年无进展生存率分别为10.6%和15.7%(P=0.033)。
- 高NLR组与低NLR组5年总生存率分别为15.5%和22.7%(P=0.012)。
- Cox多因素分析显示NLR为影响总生存的独立因素(HR=1.06,95%CI 1.003~1.135,P=0.041)。
关键数值与推荐
- 放疗前NLR最佳界值为2.1,据此将患者分为高NLR组和低NLR组。
- 420例中单纯放疗99例(23.6%),序贯放化疗139例(33.1%),同步放化疗182例(43.3%)。
临床怎么用
- 放疗前NLR可作为局部晚期NSCLC患者接受胸部放疗的预后评估指标,高NLR提示预后不良。
局限性
- NLR受患者状态和治疗影响较大,仍需进一步深入研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: The aim of this retrospective study was to evaluate the prognostic significance of pretreatment Neutrophil-to-Lymphocyte Ratio(NLR) in locally advanced non-small cell lung cancer(NSCLC) patients treated with thoracic radiotherapy. Methods: We retrospectively analyze 420 patients who received thoracic radiotherapy alone, sequential chemoraiotherapy or concurrent chemoradiotherapy for locally advanced stage NSCLC from January 2007 to December 2010 of our hospital. The patients were divided into two groups (high NLR group and low NLR group) with appropriate cutoff point using the receiver operating characteristic (ROC) curve method. The survival curve was established by Kaplan-Meier method. The Log-rank test was used to compare the survival of the two NLR groups and the multivariate analysis was carried out by Cox regression model. Results: Among the 420 patients, 99 received radiotherapy alone, 139 received sequential chemoradiotherapy and 182 received concurrent chemoradiotherapy. 345 patients died and 75 were still alive. The median follow-up time was 5.2 years and the median overall survival was 22 months. The cut-off value of pretreatment NLR was 2.1. The 5-year PFS and OS rates in high NLR group and low NLR group were 10.6% vs 15.7% (P=0.033) and 15.5% vs 22.7% (P=0.012). Multivariate analysis confirmed that pretreatment NLR (hazard ratio 1.06, P=0.041) was independent prognostic factor of OS. Conclusions: Our study revealed that the pretreatment NLR is the independent prognostic factor of OS in patients with locally advanced stage NSCLC treated with thoracic radiotherapy. However, NLR is still greatly influenced by patient's condition and treatment which needs further research. 目的: 分析放疗前中性粒细胞淋巴细胞比值(NLR)对局部晚期非小细胞肺癌(NSCLC)患者的预后评估价值。 方法: 回顾性分析2007年1月至2010年12月中国医学科学院肿瘤医院收治的420例接受单纯放疗、序贯放化疗或同步放化疗局部晚期NSCLC患者的临床和随访资料。分析患者放疗前外周血NLR与临床的相关性,通过建立受试者工作特征曲线(ROC),获得最佳界值,将患者分为高NLR组和低NLR组,通过Kaplan-Meier法绘制患者的生存曲线,log rank法比较高NLR组和低NLR组患者的生存,通过Cox比例风险回归模型进行多因素分析。 结果: 420例患者中,接受单纯放疗、序贯放化疗和同步放化疗者分别为99例(23.6%)、139例(33.1%)和182例(43.3%)。全组有75例患者生存,中位随访时间为5.2年,中位生存时间为22个月。放疗前NLR的最佳界值为2.1。放疗前高NLR组和低NLR组患者的5年无进展生存率分别为10.6%和15.7%(P=0.033),5年总生存率分别为15.5%和22.7%(P=0.012)。Cox多因素分析显示,NLR为影响局部晚期NSCLC患者预后的独立因素(HR=1.06,95%CI为1.003~1.135,P=0.041)。 结论: 放疗前NLR升高对于接受放疗的局部晚期NSCLC患者,是独立的不良预后因素,但NLR受患者状态和治疗影响较大,仍需进一步深入研究。.
引用
- Dong X, Zhou ZM, Bi N, et al. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29936771. doi:10.3760/cma.j.issn.0253-3766.2018.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。